253 related articles for article (PubMed ID: 17100941)
21. Excess adenosine A2B receptor signaling contributes to priapism through HIF-1α mediated reduction of PDE5 gene expression.
Ning C; Wen J; Zhang Y; Dai Y; Wang W; Zhang W; Qi L; Grenz A; Eltzschig HK; Blackburn MR; Kellems RE; Xia Y
FASEB J; 2014 Jun; 28(6):2725-35. PubMed ID: 24614760
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury.
Ahn BO; Kang KK; Ahn GJ; Kwon JW; Kim WB; Kang KS; Lee YS
Int J Impot Res; 2003 Dec; 15(6):405-11. PubMed ID: 14671658
[TBL] [Abstract][Full Text] [Related]
23. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
Zhang XH; Morelli A; Luconi M; Vignozzi L; Filippi S; Marini M; Vannelli GB; Mancina R; Forti G; Maggi M
Eur Urol; 2005 Mar; 47(3):409-16; discussion 416. PubMed ID: 15716209
[TBL] [Abstract][Full Text] [Related]
24. Glucose-6-phosphate dehydrogenase deficiency associated stuttering priapism: report of a case.
Finley DS
J Sex Med; 2008 Dec; 5(12):2963-6. PubMed ID: 18823322
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase type 5 regulation in the penile corpora cavernosa.
Lin CS
J Sex Med; 2009 Mar; 6 Suppl 3():203-9. PubMed ID: 19267844
[TBL] [Abstract][Full Text] [Related]
26. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.
Burnett AL; Anele UA; Trueheart IN; Strouse JJ; Casella JF
Am J Med; 2014 Jul; 127(7):664-8. PubMed ID: 24680796
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape.
Musicki B; Burnett AL
Expert Opin Ther Targets; 2020 May; 24(5):439-450. PubMed ID: 32191546
[No Abstract] [Full Text] [Related]
29. Daily tadalafil for the chronic phase of stuttering priapism: a case report.
Massenio P; D'Altilia N; Sanguedolce F; Carrieri G; Cormio L
BMC Urol; 2018 May; 18(1):54. PubMed ID: 29855284
[TBL] [Abstract][Full Text] [Related]
30. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
31. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
32. New insights into the pathophysiology of sickle cell disease-associated priapism.
Bivalacqua TJ; Musicki B; Kutlu O; Burnett AL
J Sex Med; 2012 Jan; 9(1):79-87. PubMed ID: 21554553
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology of erectile dysfunction in man.
Cirino G; Fusco F; Imbimbo C; Mirone V
Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277
[TBL] [Abstract][Full Text] [Related]
34. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Lin G; Xin ZC; Lue TF; Lin CS
J Urol; 2003 Aug; 170(2 Pt 2):S15-8; discussion S19. PubMed ID: 12853767
[TBL] [Abstract][Full Text] [Related]
35. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
36. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
Joice GA; Liu JL; Burnett AL
BJU Int; 2021 May; 127(5):498-506. PubMed ID: 33606327
[TBL] [Abstract][Full Text] [Related]
37. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes.
Hoeh MP; Levine LA
J Sex Med; 2014 Jan; 11(1):197-204. PubMed ID: 24433561
[TBL] [Abstract][Full Text] [Related]
38. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
39. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
Pickard R
Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
[No Abstract] [Full Text] [Related]
40. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
